DCPH - Deciphera Pharma prices $125M stock offering at 18.00/share

• Deciphera Pharmaceuticals ( NASDAQ: DCPH ) has priced an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00/share, for expected gross proceeds expected to be ~$125M.
• Underwriters are granted a 30-day option to purchase up to an additional 1,041,666 shares of common stock at the public offering price.
• Offering is expected to close on January 24, 2023.
• All of the shares of common stock are being offered by Deciphera.
• Net proceeds from the offering will be used to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only; to fund the development of its pipeline; and the remainder for working capital purposes, including general operating expenses.

For further details see: